Evaluation of PKU UP

Last updated: February 17, 2026
Sponsor: Vitaflo International, Ltd
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Phenylketonuria

Treatment

PKU UP

Clinical Study ID

NCT05995717
PKU-PAED-LIQ-2022-10-07
327641
23/NW/0185
  • Ages 1-10
  • All Genders

Study Summary

PKU UP is a prospective, single-arm, open-label, 26-week acceptability study to evaluate PKU UP for the dietary management of participants with phenylketonuria (PKU). Up to 15 participants aged 1 - 10 years old will be recruited and it is anticipated the study will open in at least three sites in the United Kingdom (UK) to recruit the target number of participants in the required timeframe.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of PKU requiring a low-protein diet and protein substitute.

  • Participants who are adherent with their blood phenylalanine (Phe) testing, in theopinion of the investigator.

  • Participants aged 1-10 years.

  • Participants who in the opinion of the investigator are anticipated to be able totake at least half of their daily protein equivalent requirement from PKU UP (inorder to assess this, a taste test (or similar) may be conducted at investigator'sdiscretion as part of the screening process).

  • Willingly given, written, informed consent from the parent(s)/guardian(s).

  • Willingly given, written assent by the participant (if appropriate).

Exclusion

Exclusion Criteria:

  • Inability to comply with the study protocol, in the opinion of the investigator.

  • Any co-morbidity, which, in the opinion of the investigator, would precludeparticipation in the study.

  • Diagnosis of persistent hyperphenylalaninemia, or mild PKU not requiring a lowprotein diet and protein substitute.

  • Allergy or intolerance to milk.

  • Participants who are currently participating in, plan to participate in or haveparticipated in an interventional investigational drug, food or medical device studywithin 30 days prior to the screening visit.

  • Use of additional micronutrient supplements during the evaluation period, unlessclinically indicated and prescribed by the Investigator (must be recorded in boththe medical records and case report form).

Study Design

Total Participants: 16
Treatment Group(s): 1
Primary Treatment: PKU UP
Phase:
Study Start date:
January 11, 2024
Estimated Completion Date:
May 31, 2026

Study Description

PKU is a rare inborn error of metabolism with a prevalence of 1 in 10,000 in the UK population. The mainstay of treatment for most individuals is dietary therapy with a strict protein-restricted diet. We propose to recruit children with a diagnosis of PKU aged 1-10 years.

The study product, PKU UP, is a food for special medical purposes (FSMP), as defined by the Delegated Act EU 2016/128, used for the dietary management of Phenylketonuria (PKU).

The study will be investigating the acceptability of PKU UP, as defined by the Advisory Committee on Borderline Substances (ACBS). This includes the following:

  • participant adherence to recommended intakes

  • gastrointestinal symptoms

  • evaluations of palatability.

Each participant will be on the study for 26 weeks. This includes evaluation part 1 and evaluation part 2:

  • Part 1 consists of a 12 week period where participants introduce the study product into their diet. Gastrointestinal tolerance, metabolic control, compliance, product acceptability and dietary quality will be evaluated.

  • Part 2 consists of a 14 week period where participants continue to take the study product for a longer assessment of growth and nutritional status.

Data collection will be performed using paper and/or electronic Case Report Forms completed by the investigators at the baseline, evaluation periods and end of study visits. There will also be three questionnaires completed by the parents/guardians over the course of the study, in relation to protein substitute intake, gastrointestinal tolerance, and product acceptability.

Connect with a study center

  • Royal Belfast Hospital for Sick Children

    Belfast, BT12 6BE
    United Kingdom

    Site Not Available

  • Royal Belfast Hospital for Sick Children

    Belfast 2655984, BT12 6BE
    United Kingdom

    Site Not Available

  • Birmingham Children's Hospital

    Birmingham, B4 6NH
    United Kingdom

    Site Not Available

  • Birmingham Children's Hospital

    Birmingham 2655603, B4 6NH
    United Kingdom

    Site Not Available

  • St. Luke's Hospital

    Bradford, BD5 0NA
    United Kingdom

    Site Not Available

  • St. Luke's Hospital

    Bradford 2654993, BD5 0NA
    United Kingdom

    Site Not Available

  • University Hospitals Bristol and Weston NHS Foundation Trust

    Bristol, BS2 8BJ
    United Kingdom

    Site Not Available

  • University Hospitals Bristol and Weston NHS Foundation Trust

    Bristol 2654675, BS2 8BJ
    United Kingdom

    Site Not Available

  • Leicester Royal Infirmary

    Leicester, LE1 5WW
    United Kingdom

    Site Not Available

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, WC1N 3JH
    United Kingdom

    Site Not Available

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London 2643743, WC1N 3JH
    United Kingdom

    Site Not Available

  • Nottingham Children's Hospital

    Nottingham, NG7 2UH
    United Kingdom

    Site Not Available

  • Nottingham Children's Hospital

    Nottingham 2641170, NG7 2UH
    United Kingdom

    Site Not Available

  • Sheffield Children's Hospital

    Sheffield, S10 2TH
    United Kingdom

    Site Not Available

  • Sheffield Children's Hospital

    Sheffield 2638077, S10 2TH
    United Kingdom

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.